Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Exp Dermatol ; 21(9): 706-9, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22897578

RESUMO

Sézary syndrome (SS) is an aggressive cutaneous T-cell lymphoma with CD4+ tumor cells localized in the skin, lymph nodes and peripheral blood. Characteristic molecular aberrancies in SS have been identified; however, paucity of functional models severely hampered the translation of these observations into pathogenic mechanisms, and subsequent validation of novel therapeutic targets. We therefore developed a mouse model for SS using intrahepatic injection of SS cells in newborn immunodeficient RAG2(-/-) γc(-/-) mice that are completely devoid of T-, B- and NK-cell activity. Injection of the SS cell line SeAx led to long-term and reproducible systemic repopulation of the mice. Injection of mice with the SS cell line HuT-78 led to the death of the mice owing to massive growth of internal tumors. Four weeks after injection of primary SS cells, human CD3+ T cells could be tracked back in the liver, peripheral blood, lymph nodes, spleen and skin of the mice, although the engraftment rate varied when using cells from different patients. In conclusion, we demonstrate that injection of SS cell lines or primary cells in newborn RAG2(-/-) γc(-/-) mice results in long-term systemic repopulation of the mice, thereby providing a novel mouse model for Sézary syndrome.


Assuntos
Proteínas de Ligação a DNA/genética , Modelos Animais de Doenças , Síndrome de Sézary/patologia , Neoplasias Cutâneas/patologia , Animais , Linfócitos T CD4-Positivos/transplante , Humanos , Subunidade alfa de Receptor de Interleucina-2/metabolismo , Antígeno Ki-67/metabolismo , Linfonodos/metabolismo , Camundongos , Camundongos Knockout , Camundongos SCID , Transplante de Neoplasias , Síndrome de Sézary/imunologia , Síndrome de Sézary/metabolismo , Neoplasias Cutâneas/imunologia , Neoplasias Cutâneas/metabolismo
2.
Clin Cancer Res ; 18(9): 2613-24, 2012 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-22351690

RESUMO

PURPOSE: Early detection of colorectal cancer (CRC) and its precursor lesions is an effective approach to reduce CRC mortality rates. This study aimed to identify novel protein biomarkers for the early diagnosis of CRC. EXPERIMENTAL DESIGN: Proximal fluids are a rich source of candidate biomarkers as they contain high concentrations of tissue-derived proteins. The FabplCre;Apc(15lox/+) mouse model represents early-stage development of human sporadic CRC. Proximal fluids were collected from normal colon and colon tumors and subjected to in-depth proteome profiling by tandem mass spectrometry. Carcinoembryonic antigen (CEA) and CHI3L1 human serum protein levels were determined by ELISA. RESULTS: Of the 2,172 proteins identified, quantitative comparison revealed 192 proteins that were significantly (P < 0.05) and abundantly (>5-fold) more excreted by tumors than by controls. Further selection for biomarkers with highest specificity and sensitivity yielded 52 candidates, including S100A9, MCM4, and four other proteins that have been proposed as candidate biomarkers for human CRC screening or surveillance, supporting the validity of our approach. For CHI3L1, we verified that protein levels were significantly increased in sera from patients with adenomas and advanced adenomas compared with control individuals, in contrast to the CRC biomarker CEA. CONCLUSION: These data show that proximal fluid proteome profiling with a mouse tumor model is a powerful approach to identify candidate biomarkers for early diagnosis of human cancer, exemplified by increased CHI3L1 protein levels in sera from patients with CRC precursor lesions.


Assuntos
Adenoma/diagnóstico , Biomarcadores Tumorais/metabolismo , Neoplasias Colorretais/diagnóstico , Lesões Pré-Cancerosas/diagnóstico , Proteoma/análise , Adenoma/metabolismo , Adipocinas/metabolismo , Animais , Antígeno Carcinoembrionário/metabolismo , Estudos de Casos e Controles , Proteína 1 Semelhante à Quitinase-3 , Cromatografia Líquida , Colo/metabolismo , Neoplasias Colorretais/metabolismo , Detecção Precoce de Câncer , Ensaio de Imunoadsorção Enzimática , Feminino , Glicoproteínas/metabolismo , Humanos , Lectinas/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Lesões Pré-Cancerosas/metabolismo , Reto/metabolismo , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz
3.
J Invest Dermatol ; 131(3): 762-8, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21085192

RESUMO

MicroRNAs (miRNAs) are small RNAs that control gene expression, and are involved in the regulation of fundamental biological processes including development, cell differentiation, proliferation, and apoptosis. miRNAs regulate gene expression in normal hematopoiesis, and aberrant miRNA expression might contribute to leukomogenesis. Specifically, miR-21 is abundantly expressed in various tumors including leukemia and lymphoma, and is functionally involved in oncogenic processes. We investigated a role for miR-21 in Sézary Syndrome (SS), a cutaneous T-cell lymphoma (CTCL) with CD4+ tumor cells (Sézary cells) present in the skin, lymph nodes, and peripheral blood. It was shown previously that SS is characterized by constitutively activated signal transducer and activator of transcription 3 (STAT3) signaling. In this study we show by chromatin immunoprecipitation that miR-21 is a direct STAT3 target in Sézary cells. Stimulation of Sézary cells or healthy CD4+ T cells with the common-γ chain cytokine IL-21 results in a strong activation of STAT3, and subsequent upregulation of miR-21 expression. Both pri- and mature miR-21 expression are increased in Sézary cells when compared with CD4+ T cells from healthy donors. Silencing of miR-21 in Sézary cells results in increased apoptosis, suggesting a functional role for miR-21 in the leukomogenic process. Consequently, miR-21 might represent a therapeutic target for the treatment of SS.


Assuntos
Linfócitos T CD4-Positivos/metabolismo , MicroRNAs/metabolismo , Fator de Transcrição STAT3/metabolismo , Síndrome de Sézary/metabolismo , Neoplasias Cutâneas/metabolismo , Idoso , Apoptose/fisiologia , Linfócitos T CD4-Positivos/patologia , Linhagem Celular Tumoral , Feminino , Humanos , Interleucinas/metabolismo , Masculino , Síndrome de Sézary/patologia , Transdução de Sinais/fisiologia , Neoplasias Cutâneas/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA